| Year |
Citation |
Score |
| 2020 |
Sowamber R, Nelson O, Dodds L, DeCastro V, Paudel I, Milea A, Considine M, Cope L, Pinto A, Schlumbrecht M, Slomovitz B, Shaw PA, George SHL. Integrative Transcriptome Analyses of the Human Fallopian Tube: Fimbria and Ampulla-Site of Origin of Serous Carcinoma of the Ovary. Cancers. 12. PMID 32349388 DOI: 10.3390/Cancers12051090 |
0.39 |
|
| 2019 |
MacGregor HL, Sayad A, Elia A, Wang BX, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. Journal For Immunotherapy of Cancer. 7: 357. PMID 31892360 DOI: 10.1186/S40425-019-0816-5 |
0.353 |
|
| 2019 |
Colombo I, Garg S, Danesh A, Bruce J, Shaw P, Tan Q, Quevedo R, Braunstein M, Oza AM, Pugh T, Lheureux S. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a -mutated low-grade serous ovarian cancer patient. Cold Spring Harbor Molecular Case Studies. 5. PMID 31836588 DOI: 10.1101/mcs.a004341 |
0.305 |
|
| 2019 |
Yeung T, Fung O, Bashkurov M, Khandani A, Subedar O, Wudwud A, Shaw P, Clarke B, Bartlett J, Rottapel R, Kapus A. Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models. Oncotarget. 10: 6691-6712. PMID 31803363 DOI: 10.18632/Oncotarget.27330 |
0.337 |
|
| 2019 |
MacGregor HL, Garcia-Batres C, Sayad A, Elia A, Berman HK, Toker A, Katz SR, Shaw PA, Clarke BA, Crome SQ, Robert-Tissot C, Bernardini MQ, Nguyen LT, Ohashi PS. Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer. Oncoimmunology. 8: e1665460. PMID 31741762 DOI: 10.1080/2162402X.2019.1665460 |
0.33 |
|
| 2019 |
Chui MH, Doodnauth SA, Erdmann N, Tiedemann RE, Sircoulomb F, Drapkin R, Shaw P, Rottapel R. Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma. Cancer Research. PMID 31530568 DOI: 10.1158/0008-5472.Can-18-3029 |
0.382 |
|
| 2019 |
Sowamber R, Chehade R, Bitar M, Dodds LV, Milea A, Slomovitz B, Shaw PA, George SHL. CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma. Ebiomedicine. PMID 31078521 DOI: 10.1016/J.Ebiom.2019.05.002 |
0.325 |
|
| 2019 |
Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, et al. mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 30659026 DOI: 10.1136/Ijgc-2018-000087 |
0.423 |
|
| 2019 |
Tone AA, McCuaig J, Virtanen C, Zhang T, Ricker N, Romagnuolo T, Stickle N, Kim RH, Stuart-McEwan T, Shaw P, Oza AM, Kamel-Reid S, Stockley T, Bernardini MQ. The prevent ovarian cancer program (POCP): Identification of ovarian cancer-associated mutations in self-referring women from low-risk families Gynecologic Oncology. 154: 78. DOI: 10.1016/J.Ygyno.2019.04.185 |
0.389 |
|
| 2019 |
George S, Sowamber R, Dodds L, Jordan SE, Paudel I, Huang M, Pinto A, Schlumbrecht MP, Shaw P, Slomovitz BM. Hormonal receptor expression and clinical outcome in ovarian high-grade serous carcinoma Gynecologic Oncology. 154: 73. DOI: 10.1016/J.Ygyno.2019.04.173 |
0.315 |
|
| 2018 |
Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, ... Shaw PA, et al. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Medicine. 10: 81. PMID 30382883 DOI: 10.1186/S13073-018-0590-X |
0.35 |
|
| 2018 |
Visvanathan K, Shaw P, May BJ, Bahadirli-Talbot A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM. Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study. Cancer Prevention Research (Philadelphia, Pa.). PMID 30232083 DOI: 10.1158/1940-6207.Capr-18-0009 |
0.359 |
|
| 2018 |
Dickson BC, Lum A, Swanson D, Bernardini MQ, Colgan TJ, Shaw PA, Yip S, Lee CH. Novel EPC1 gene fusions in endometrial stromal sarcoma. Genes, Chromosomes & Cancer. PMID 30144186 DOI: 10.1002/Gcc.22649 |
0.354 |
|
| 2018 |
Toker A, Nguyen LT, Stone SC, Yang C, Katz SR, Shaw PA, Clarke BA, Ghazarian DA, Al Habeeb AS, Easson AM, Leong W, McCready D, Reedijk M, Guidos CJ, Pugh TJ, et al. Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30065096 DOI: 10.1158/1078-0432.Ccr-18-0554 |
0.394 |
|
| 2018 |
McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, et al. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Journal of Medical Genetics. PMID 30042185 DOI: 10.1136/Jmedgenet-2018-105472 |
0.354 |
|
| 2018 |
Cybulska P, Stewart JM, Sayad A, Virtanen C, Shaw PA, Clarke B, Stickle N, Bernardini MQ, Neel BG. A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. The American Journal of Pathology. PMID 29458007 DOI: 10.1016/J.Ajpath.2018.01.019 |
0.409 |
|
| 2018 |
Ethier J, Bonilla L, Boross-Harmer S, Bouchard-Fortier G, Cipollone J, Clarke BA, Dhani NC, Easson AM, Franke N, Goldstein DP, Lheureux S, Majeed H, May T, Reedijk M, Rouzbahman M, ... ... Shaw PA, et al. A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial. Journal of Clinical Oncology. 36: TPS5611-TPS5611. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps5611 |
0.323 |
|
| 2017 |
Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nature Communications. 8: 990. PMID 29042553 DOI: 10.1038/S41467-017-01217-9 |
0.334 |
|
| 2017 |
de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, Foulkes WD, Clarke BA. DICER1 Mutations are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. The American Journal of Surgical Pathology. PMID 28654427 DOI: 10.1097/Pas.0000000000000895 |
0.36 |
|
| 2017 |
Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, ... ... Shaw PA, et al. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016703439. PMID 28398847 DOI: 10.1200/Jco.2016.70.3439 |
0.409 |
|
| 2017 |
Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713677. PMID 28221868 DOI: 10.1200/Jco.2016.71.3677 |
0.415 |
|
| 2017 |
Akbari MR, Zhang S, Cragun D, Lee JH, Coppola D, McLaughlin J, Risch HA, Rosen B, Shaw P, Sellers TA, Schildkraut J, Narod SA, Pal T. Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. Familial Cancer. PMID 28176205 DOI: 10.1007/S10689-017-9973-1 |
0.428 |
|
| 2017 |
Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, Milea A, Sowamber R, Katz SR, Bernardini MQ, Clarke BA, ... Shaw PA, et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nature Medicine. PMID 28165478 DOI: 10.1038/Nm.4278 |
0.316 |
|
| 2017 |
Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecologic Oncology. PMID 28062115 DOI: 10.1016/J.Ygyno.2016.12.002 |
0.377 |
|
| 2017 |
Kanjanapan Y, Lheureux S, May T, Wilson MK, Bernardini M, Shaw PA, Vergote I, Brenton JD, Provencher DM, McNeish IA, Ghatage P, Ledermann JA, Colombo N, Gourley C, Weberpals J, et al. Phase II open-label randomized multi-centre study of neoadjuvant olaparib in patients (pts) with platinum sensitive (PS) relapsed high grade serous ovarian cancer (OC): The NEO trial. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps5608 |
0.364 |
|
| 2017 |
Lheureux S, Burnier JV, Tan Q, Kanjanapan Y, Clarke B, Tinker A, Ghatage P, Dhani NC, Butler MO, Welch S, Weberpals JI, Tan DSP, Brooks K, Ramsahai J, Wang L, ... Shaw PA, et al. Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret phase II consortium. Journal of Clinical Oncology. 35: 5522-5522. DOI: 10.1200/Jco.2017.35.15_Suppl.5522 |
0.305 |
|
| 2017 |
George SH, Nelson O, Sowamber R, Milea A, Xu X, Huang M, Schlumbrecht MP, Pearson JM, Shaw P, Slomovitz B. Antioxidant gene expression program is deregulated early in serous ovarian cancer Gynecologic Oncology. 145: 130. DOI: 10.1016/J.Ygyno.2017.03.304 |
0.362 |
|
| 2016 |
Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, ... ... Shaw P, et al. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine. 8: 109. PMID 27782854 DOI: 10.1186/S13073-016-0364-2 |
0.357 |
|
| 2016 |
Lo CS, Sanii S, Kroeger DR, Milne K, Talhouk A, Chiu DS, Rahimi K, Shaw PA, Clarke BA, Nelson BH. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumor-infiltrating lymphocyte response with distinct implications for immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27601594 DOI: 10.1158/1078-0432.Ccr-16-1433 |
0.384 |
|
| 2016 |
Shaw PA, Clarke BA. Prophylactic Gynecologic Specimens from Hereditary Cancer Carriers. Surgical Pathology Clinics. 9: 307-28. PMID 27241111 DOI: 10.1016/J.Path.2016.02.002 |
0.413 |
|
| 2016 |
Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis T, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG. Loss of SMARCA4 (BRG1) Protein Expression by Immunohistochemistry in Small Cell Carcinoma of the Ovary, Hypercalcemic Type Distinguishes these Tumors from their Mimics. Histopathology. PMID 27100627 DOI: 10.1111/His.12988 |
0.329 |
|
| 2016 |
Mandilaras V, Lheureux S, Stjepanovic N, Burnier J, Wilson MK, Wang L, Clarke B, Shaw PA, Berman HK, Kim R, Armel SR, McCuaig J, Volenik A, Ahmed L, Misyura M, et al. Germline and somatic homologous recombination gene mutations in high-grade serous ovarian cancer and clinical outcome. Journal of Clinical Oncology. 34: 5579-5579. DOI: 10.1200/Jco.2016.34.15_Suppl.5579 |
0.379 |
|
| 2016 |
Freixinos VR, Burnier J, Lheureux S, Clarke B, Tinker A, Ghatage P, Dhani N, Butler M, Mackay H, Welch S, Weberpals JI, Tonkin KS, Brooks K, Ramsahai J, Wang L, ... Shaw PA, et al. Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients (pts) with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium. Journal of Clinical Oncology. 34: 5564-5564. DOI: 10.1200/Jco.2016.34.15_Suppl.5564 |
0.331 |
|
| 2016 |
Mandilaras V, Garg S, Burnier J, Karakasis K, Wang L, Mackay H, Dhani NC, Butler MO, Rodriguez-Freixinos V, Wilson MK, Martin-Lorente C, Ethier J, Bedard PL, Siu LL, Clarke B, ... Shaw PA, et al. P53 functional mutation type in high-grade serous ovarian cancer and clinical outcomes. Journal of Clinical Oncology. 34: 5550-5550. DOI: 10.1200/Jco.2016.34.15_Suppl.5550 |
0.414 |
|
| 2016 |
Aung KL, Pugh TJ, Stockley T, Wang L, Korpanty G, Serra S, Shaw P, Tsao MS, Dhani N, Mackay H, Shepherd FA, Kamel-Reid S, Siu LL, Bedard PL. Abstract 02: Pan-cancer analysis of hotspot mutations in genes encoding the members of mitogen activated protein kinase (MAPK) and phosphoinosidtide-3 kinase (PI3K) pathways among smokers and non-smokers Clinical Cancer Research. 22: 2-2. DOI: 10.1158/1557-3265.Pmsclingen15-02 |
0.372 |
|
| 2016 |
Lheureux S, Yang C, Shaw P, Clarke B, Tsao J, Karakasis K, Butler M, Salman N, Dowar M, Xu J, Poulain L, Ohashi PS, Pugh T, Oza A. Abstract A35: Elucidating mechanisms involved in long-term response to platinum-based chemotherapy in high-grade serous ovarian cancer. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A35 |
0.415 |
|
| 2016 |
George S, Milea A, Ramlogan S, Considine M, Cope L, Salman N, Shaw P. Abstract A27: Transcriptome analyses of human ampulla and fimbriae highlight similarities and differences. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-A27 |
0.403 |
|
| 2015 |
Krishnan V, Clark R, Chekmareva M, Johnson A, George S, Shaw P, Seewaldt V, Rinker-Schaeffer C. In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose. Journal of Visualized Experiments : Jove. PMID 26555178 DOI: 10.3791/52721 |
0.415 |
|
| 2015 |
Katz TA, Liao S, Palmieri VJ, Dearth RK, Pathiraja TN, Huo Z, Shaw P, Small S, Davidson NE, Peters DG, Tseng G, Oesterreich S, Lee AV. Targeted DNA methylation screen in the mouse mammary genome reveals a parity-induced hypermethylation of IGF1R which persists long after parturition. Cancer Prevention Research (Philadelphia, Pa.). PMID 26290394 DOI: 10.1158/1940-6207.Capr-15-0178 |
0.336 |
|
| 2015 |
Salmena L, Shaw P, Fan I, McLaughlin JR, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer European Journal of Gynaecological Oncology. 36: 260-267. PMID 26189250 DOI: 10.12892/Ejgo2741.2015 |
0.402 |
|
| 2015 |
Lheureux S, Shaw PA, Karakasis K, Oza AM. Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. Gynecologic Oncology. 138: 235-7. PMID 26072440 DOI: 10.1016/J.Ygyno.2015.06.014 |
0.354 |
|
| 2015 |
Wilson MK, Bedard PL, Joshua AM, Mackay H, Butler MO, Dhani NC, Lheureux S, Martin-Lorente C, Rodriguez-Freixinos V, Clarke B, Shaw P, Milea A, Wang L, Kamel-Reid S, Stockley T, et al. Molecular profiling and targeted therapy in advanced endometrial cancer. Journal of Clinical Oncology. 33: 5589-5589. DOI: 10.1200/Jco.2015.33.15_Suppl.5589 |
0.391 |
|
| 2015 |
Stjepanovic N, Wilson MK, Oza AM, Clarke B, Berman HK, Amir E, Mackay H, Shaw P, Butler MO, Mulligan AM, Milea A, Ahmed L, Volenik A, Wang L, Pugh TJ, et al. Somatic mutation profiling of advanced breast and ovarian cancers according to germline BRCA1/2 mutation status. Journal of Clinical Oncology. 33: 1532-1532. DOI: 10.1200/Jco.2015.33.15_Suppl.1532 |
0.412 |
|
| 2015 |
George SH, Sowamber R, Shaw P. Abstract POSTER-BIOL-1312: The role of BRCA and CEBPD in serous ovarian cancer carcinogenesis Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1312 |
0.429 |
|
| 2015 |
George SH, Milea A, Salman NH, Shaw PA. Abstract 2080: Differential transcription profile of epithelia in fimbria versus the ampulla of the fallopian tube Cancer Research. 75: 2080-2080. DOI: 10.1158/1538-7445.Am2015-2080 |
0.396 |
|
| 2014 |
Tan DS, Rye T, Barrie C, Shaw P, Fyles A, Laframboise S, Wang L, Gourley C, Oza AM. 878PDBENEFICIAL EFFECT OF ADJUVANT CHEMOTHERAPY AND WHOLE ABDOMINAL OR PELVIC RADIOTHERAPY (WAPRT) ON PROGRESSION FREE AND OVERALL SURVIVAL FOLLOWING PRIMARY SURGERY IN PATIENTS WITH OVARIAN CLEAR CELL CARCINOMA (OCCC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv306. PMID 28172229 DOI: 10.1093/Annonc/Mdu338.4 |
0.322 |
|
| 2014 |
Thériault BL, Cybulska P, Shaw PA, Gallie BL, Bernardini MQ. The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. Journal of Ovarian Research. 7: 123. PMID 25528264 DOI: 10.1186/S13048-014-0123-1 |
0.4 |
|
| 2014 |
Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, Semotiuk K, Holter S, Sy K, Kwon JS, Soma A, Singh N, Gallinger S, Shaw P, Arseneau J, et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. The American Journal of Surgical Pathology. 38: 1173-81. PMID 25025451 DOI: 10.1097/Pas.0000000000000298 |
0.414 |
|
| 2014 |
George SHL, Shaw P. BRCA and Early Events in the Development of Serous Ovarian Cancer. Frontiers in Oncology. 4: 5-5. PMID 24478985 DOI: 10.3389/Fonc.2014.00005 |
0.435 |
|
| 2014 |
Wu RC, Ayhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chui MH, Rosen B, Shih IeM, Wang TL. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. The Journal of Pathology. 232: 473-81. PMID 24338723 DOI: 10.1002/Path.4315 |
0.42 |
|
| 2014 |
Milea A, George SH, Matevski D, Jiang H, Madunic M, Berman HK, Gauthier ML, Gallie B, Shaw PA. Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 27: 991-1001. PMID 24336157 DOI: 10.1038/Modpathol.2013.218 |
0.394 |
|
| 2014 |
Tan DSP, Rye T, Barrie C, Shaw P, Laframboise S, Fyles AW, Wang L, Gourley C, Oza AM. Analysis of outcomes in patients (pts) with recurrent ovarian clear cell carcinoma (ROCCC): Time to rethink our approach to treatment. Journal of Clinical Oncology. 32: 5548-5548. DOI: 10.1200/Jco.2014.32.15_Suppl.5548 |
0.322 |
|
| 2014 |
Spreafico A, Oza AM, Clarke B, Mackay H, Shaw P, Rasty G, Butler MO, Dhani NC, Lheureux S, Wilson M, Welch S, Siu LL, Zhang T, Yu C, Krishna GD, et al. Genotype matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 32: 5506-5506. DOI: 10.1200/Jco.2014.32.15_Suppl.5506 |
0.406 |
|
| 2014 |
George SHL, Hurley J, Donenberg T, Dyer H, Milea A, Shaw PA. Abstract PL03-01: Origins of ovarian cancer, the biology of premalignancy, and cancer health disparities Cancer Epidemiology, Biomarkers & Prevention. 23. DOI: 10.1158/1538-7755.Disp13-Pl03-01 |
0.439 |
|
| 2013 |
McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. Journal of the National Cancer Institute. 105: 141-8. PMID 23257159 DOI: 10.1093/Jnci/Djs494 |
0.402 |
|
| 2013 |
Tran B, Brown AM, Bedard PL, Winquist E, Goss GD, Hotte SJ, Welch SA, Hirte HW, Zhang T, Stein LD, Ferretti V, Watt S, Jiao W, Ng K, Ghai S, ... Shaw P, et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial. International Journal of Cancer. Journal International Du Cancer. 132: 1547-55. PMID 22948899 DOI: 10.1002/Ijc.27817 |
0.412 |
|
| 2013 |
Jakate K, Azimi F, Ali RH, Lee CH, Clarke BA, Rasty G, Shaw PA, Melnyk N, Huntsman DG, Laframboise S, Rouzbahman M. Endometrial sarcomas: an immunohistochemical and JAZF1 re-arrangement study in low-grade and undifferentiated tumors. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 95-105. PMID 22918161 DOI: 10.1038/Modpathol.2012.136 |
0.312 |
|
| 2013 |
Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, Damaraju S, Fereday S, Winterhoff BJ, Kalloger SE, Senz J, Yang W, Steed H, Allo G, Ferguson S, ... Shaw P, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. The Journal of Pathology. 229: 111-20. PMID 22899400 DOI: 10.1002/Path.4088 |
0.375 |
|
| 2013 |
George SH, Milea A, Sowamber R, Toccalino D, Shaw PA. Abstract 4765: The role of estrogen receptor signalling in serous ovarian cancer. Cancer Research. 73: 4765-4765. DOI: 10.1158/1538-7445.Am2013-4765 |
0.384 |
|
| 2012 |
Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, ... ... Shaw PA, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 491: 399-405. PMID 23103869 DOI: 10.1038/Nature11547 |
0.372 |
|
| 2012 |
Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, ... ... Shaw PA, et al. Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine. 10: 205. PMID 23034130 DOI: 10.1186/1479-5876-10-205 |
0.393 |
|
| 2012 |
Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RB, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. Journal of the National Cancer Institute. 104: 1503-13. PMID 22923510 DOI: 10.1093/Jnci/Djs345 |
0.374 |
|
| 2012 |
Tone AA, Virtanen C, Shaw P, Brown TJ. Prolonged postovulatory proinflammatory signaling in the fallopian tube epithelium may be mediated through a BRCA1/DAB2 axis Clinical Cancer Research. 18: 4334-4344. PMID 22753593 DOI: 10.1158/1078-0432.Ccr-12-0199 |
0.335 |
|
| 2012 |
Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL. Cancer genomics: technology, discovery, and translation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 647-60. PMID 22271477 DOI: 10.1200/Jco.2011.39.2316 |
0.399 |
|
| 2012 |
Thériault BL, Pajovic S, Bernardini MQ, Shaw PA, Gallie BL. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. International Journal of Cancer. Journal International Du Cancer. 130: 1844-54. PMID 21618518 DOI: 10.1002/Ijc.26189 |
0.434 |
|
| 2012 |
Ibrahimov E, Pham N, Meng F, Sukhram M, Chadwick D, Serra S, Shaw P, Rowsell C, Law C, McPherson J, Gallinger S, Tsao M. Abstract B91: Primary tumor xenograft establishment from pancreatic resection specimens. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-B91 |
0.371 |
|
| 2012 |
Begley KN, Mukhopadhyay D, Petersen GM, Protopopov A, Thayer S, Chin L, Ibrahimov E, Shaw P, Hudson T, Gallinger S, Tsao M, Stein L, McPherson JD, Muthuswamy L, Beck T, et al. Abstract A9: The pancreatic ductal adenocarcinoma project at the Ontario Institute for Cancer Research. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A9 |
0.364 |
|
| 2012 |
Stewart JM, Shaw PA, Bernardini MQ, Ailles LE, Neel BG. Abstract 3318: Phenotypic heterogeneity and instability of tumor-initiating cells in high-grade serous cancer Cancer Research. 72: 3318-3318. DOI: 10.1158/1538-7445.Am2012-3318 |
0.396 |
|
| 2011 |
Shaw PA. Hereditary Carcinomas of the Ovary, Fallopian Tube, and Peritoneum. Surgical Pathology Clinics. 4: 461-78. PMID 26837301 DOI: 10.1016/J.Path.2010.03.003 |
0.461 |
|
| 2011 |
George SH, Greenaway J, Milea A, Clary V, Shaw S, Sharma M, Virtanen C, Shaw PA. Identification of abrogated pathways in fallopian tube epithelium from BRCA1 mutation carriers. The Journal of Pathology. 225: 106-17. PMID 21744340 DOI: 10.1002/Path.2927 |
0.444 |
|
| 2011 |
Elschenbroich S, Ignatchenko V, Clarke B, Kalloger SE, Boutros PC, Gramolini AO, Shaw P, Jurisica I, Kislinger T. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry. Journal of Proteome Research. 10: 2286-99. PMID 21491939 DOI: 10.1021/Pr1011087 |
0.389 |
|
| 2011 |
Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG, Ailles LE. Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 6468-73. PMID 21451132 DOI: 10.1073/Pnas.1005529108 |
0.378 |
|
| 2011 |
Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, Fan I, Bradley L, Shaw PA, Narod SA. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecologic Oncology. 121: 353-7. PMID 21324516 DOI: 10.1016/J.Ygyno.2011.01.020 |
0.421 |
|
| 2011 |
Tone AA, Virtanen C, Shaw PA, Brown TJ. Decreased progesterone receptor isoform expression in luteal phase fallopian tube epithelium and high-grade serous carcinoma. Endocrine-Related Cancer. 18: 221-34. PMID 21263043 DOI: 10.1530/Erc-10-0235 |
0.344 |
|
| 2011 |
George SHL, Milea A, Gauthier M, Shaw PA. Abstract A11: Loss of LKB1 is an early event in high-grade serous carcinoma Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A11 |
0.483 |
|
| 2011 |
Milea AL, George S, Berman HK, Gauthier ML, Shaw PA. Abstract 333: The role of the retinoblastoma pathway (Rb) in high grade serous ovarian varcinoma (HGSC) Cancer Research. 71: 333-333. DOI: 10.1158/1538-7445.Am2011-333 |
0.416 |
|
| 2011 |
George SH, Greenaway J, Milea AL, Virtanen C, Shaw PA. Abstract 2835: BRCA1 signature in high-risk fallopian tube epithelium Cancer Research. 71: 2835-2835. DOI: 10.1158/1538-7445.Am2011-2835 |
0.46 |
|
| 2011 |
Tran B, Dancey JE, Bedard PL, Kamel-Reid S, McPherson JD, Stein LD, Brown AM, Zhang T, Watt S, Ferretti V, Ghai S, Petrocelli T, Shaw P, Neel BG, Onetto N, et al. Abstract B48: Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B48 |
0.392 |
|
| 2011 |
Theriault BL, Pajovic S, Bernardini MQ, Shaw PA, Lim H, Gallie BL. Abstract A186: KIF14 is a novel therapeutic target for ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A186 |
0.451 |
|
| 2010 |
Nguyen LT, Yen PH, Nie J, Liadis N, Ghazarian D, Al-Habeeb A, Easson A, Leong W, Lipa J, McCready D, Reedijk M, Hogg D, Joshua AM, Quirt I, Messner H, ... Shaw P, et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). Plos One. 5: e13940. PMID 21085676 DOI: 10.1371/Journal.Pone.0013940 |
0.336 |
|
| 2010 |
Vicus D, Shaw PA, Finch A, Rosen B, Murphy J, Armel S, Sun P, Narod SA. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecologic Oncology. 118: 295-8. PMID 20722102 DOI: 10.1016/J.Ygyno.2010.05.012 |
0.306 |
|
| 2010 |
Freedman OC, Dodge J, Shaw P, Oza AM, Bernadini M, Klachook S, Murphy KJ, Lo E, Rosen B, Mackay H. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecologic Oncology. 119: 22-5. PMID 20591472 DOI: 10.1016/J.Ygyno.2010.06.002 |
0.347 |
|
| 2010 |
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, ... ... Shaw PA, et al. International network of cancer genome projects. Nature. 464: 993-8. PMID 20393554 DOI: 10.1038/Nature08987 |
0.372 |
|
| 2010 |
May T, Virtanen C, Sharma M, Milea A, Begley H, Rosen B, Murphy KJ, Brown TJ, Shaw PA. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecologic Oncology. 117: 9-17. PMID 20117829 DOI: 10.1016/J.Ygyno.2010.01.006 |
0.335 |
|
| 2010 |
Stewart JM, Shaw PA, Virtanen C, Gedye C, Ailles L, Bernardini M, Neel BG. Abstract 4303: Definitive identification and characterization of ovarian cancer-initiating cells Cancer Research. 70: 4303-4303. DOI: 10.1158/1538-7445.Am10-4303 |
0.301 |
|
| 2009 |
Shaw PA, Rouzbahman M, Pizer ES, Pintilie M, Begley H. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 22: 1133-8. PMID 19543244 DOI: 10.1038/Modpathol.2009.89 |
0.407 |
|
| 2008 |
Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4067-78. PMID 18593983 DOI: 10.1158/1078-0432.Ccr-07-4959 |
0.388 |
|
| 2008 |
Milosevic M, Lunt SJ, Leung E, Skliarenko J, Shaw P, Fyles A, Hill RP. Interstitial permeability and elasticity in human cervix cancer. Microvascular Research. 75: 381-390. PMID 18187164 DOI: 10.1016/J.Mvr.2007.11.003 |
0.328 |
|
| 2008 |
Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, Rosen B, Shaw P, Jurisica I, Kislinger T. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. Journal of Proteome Research. 7: 339-51. PMID 18076136 DOI: 10.1021/Pr0703223 |
0.372 |
|
| 2008 |
Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecologic Oncology. 108: 385-94. PMID 18036641 DOI: 10.1016/J.Ygyno.2007.10.035 |
0.398 |
|
| 2008 |
Menzies RJ, Bukhman YV, Ng NF, Shaw PA, Mak TW. Genomic And Transcriptome Profiling Of Epithelial Ovarian Cancer Clinical and Investigative Medicine. 31: 17. DOI: 10.25011/Cim.V31I4.4817 |
0.442 |
|
| 2007 |
Motamed-Khorasani A, Jurisica I, Letarte M, Shaw PA, Parkes RK, Zhang X, Evangelou A, Rosen B, Murphy KJ, Brown TJ. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression. Oncogene. 26: 198-214. PMID 16832351 DOI: 10.1038/Sj.Onc.1209773 |
0.45 |
|
| 2007 |
May T, Sharma M, Jurisica I, Rosen B, Murphy J, Shaw P, Brown T. Characterization of low grade serous carcinoma of the ovary and its precursorss Clinical & Investigative Medicine. 30: 88. DOI: 10.25011/Cim.V30I4.2865 |
0.397 |
|
| 2006 |
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Journal of the National Cancer Institute. 98: 1694-706. PMID 17148771 DOI: 10.1093/Jnci/Djj465 |
0.404 |
|
| 2006 |
Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecologic Oncology. 100: 58-64. PMID 16137750 DOI: 10.1016/J.Ygyno.2005.06.065 |
0.333 |
|
| 2005 |
Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF. High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer Neoplasia. 7: 603-613. PMID 16036111 DOI: 10.1593/Neo.04760 |
0.322 |
|
| 2005 |
Motamed-Khorasani A, Letarte M, Jurisica I, Shaw P, Murphy K, Brown T. Androgen-Induced Altered Gene Expression Profiles in Ovarian Epithelial Cells From BRCA1 and 2 Mutation Carriers as Compared to Cells From Control Patients Fertility and Sterility. 84: S440. DOI: 10.1016/J.Fertnstert.2005.07.1150 |
0.372 |
|
| 2003 |
Grisaru DA, Covens A, Franssen E, Chapman W, Shaw P, Colgan T, Murphy J, DePetrillo D, Lickrish G, Laframboise S, Rosen B. Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma. Cancer. 97: 1904-1908. PMID 12673716 DOI: 10.1002/Cncr.11269 |
0.331 |
|
| 2002 |
Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, Ryan A, Menko FH, Kenemans P, Jacobs IJ. Histopathologic features of genetically determined ovarian cancer. International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists. 21: 407-11. PMID 12352190 DOI: 10.1097/00004347-200210000-00011 |
0.421 |
|
| 2002 |
Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, Colgan T, Chapman W, Shaw P. How important is removal of the parametrium at surgery for carcinoma of the cervix Gynecologic Oncology. 84: 145-149. PMID 11748991 DOI: 10.1006/Gyno.2001.6493 |
0.331 |
|
| 2002 |
Covens A, Rosen B, Murphy J, Laframboise S, Depetrillo AD, Lickrish G, Colgan T, Chapman W, Shaw P. How important is removal of the parametrium at surgery for carcinoma of the cervix Obstetrical & Gynecological Survey. 57: 285-286. DOI: 10.1097/00006254-200205000-00014 |
0.34 |
|
| 2001 |
Covens A, Rosen B, Murphy J, Laframboise S, DePetrillo AD, Lickrish G, Colgan T, Chapman W, Shaw P. Changes in the Demographics and Perioperative Care of Stage IA2/IB1 Cervical Cancer over the Past 16 Years Gynecologic Oncology. 81: 133-137. PMID 11330939 DOI: 10.1006/Gyno.2001.6158 |
0.334 |
|
| 2001 |
Shaw PA, Rittenberg PV, Brown TJ. Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer. Gynecologic Oncology. 80: 132-8. PMID 11161850 DOI: 10.1006/Gyno.2000.6068 |
0.399 |
|
| 1999 |
Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuck A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. Journal of Clinical Pathology. 52: 372-5. PMID 10560359 DOI: 10.1136/Jcp.52.5.372 |
0.331 |
|
| 1999 |
Brown TJ, Shaw PA, Karp X, Huynh MH, Begley H, Ringuette MJ. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology. 75: 25-33. PMID 10502421 DOI: 10.1006/Gyno.1999.5552 |
0.416 |
|
| 1999 |
Covens A, Kirby J, Shaw P, Chapman W, Franseen E. Prognostic Factors for Relapse and Pelvic Lymph Node Metastases in Early Stage I Adenocarcinoma of the Cervix Gynecologic Oncology. 74: 423-427. PMID 10479503 DOI: 10.1006/Gyno.1999.5466 |
0.302 |
|
| 1999 |
Zweemer RP, Verheijen RH, Menko FH, Gille JJ, van Diest PJ, Coebergh JW, Shaw PA, Jacobs IJ, Kenemans P. Differences between hereditary and sporadic ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 82: 151-3. PMID 10206407 DOI: 10.1016/S0301-2115(98)00218-8 |
0.327 |
|
| 1997 |
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer Nature Medicine. 3: 227-230. PMID 9018244 DOI: 10.1038/Nm0297-227 |
0.382 |
|
| 1990 |
Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic Fluid from Human Ovarian Cancer Patients Contains Growth Factors Necessary for Intraperitoneal Growth of Human Ovarian Adenocarcinoma Cells Journal of Clinical Investigation. 86: 851-855. PMID 2394835 DOI: 10.1172/Jci114784 |
0.325 |
|
| Show low-probability matches. |